Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (Nasdaq: AZTA) is a global leader in life sciences solutions, providing essential tools for drug development, clinical research, and genomic discovery. This page aggregates official press releases and verified news about the company’s advancements in cold-chain sample management, automated storage systems, and multiomics services.
Investors and researchers will find timely updates on Azenta’s operational milestones, including earnings reports, strategic partnerships, product innovations, and industry recognition. The curated content addresses key areas such as sample integrity technologies, genomic data accuracy, and global service expansions.
Key updates include developments from Azenta’s core segments: Life Sciences Products (automated storage solutions, lab consumables) and Life Sciences Services (genomic sequencing, multiomics analytics). Content is organized to help stakeholders track progress in critical research areas like precision medicine and biotherapeutic development.
Bookmark this page for streamlined access to Azenta’s latest announcements, or check regularly for insights into how the company continues to shape the future of life sciences infrastructure and biomedical innovation.
Azenta, Inc. (Nasdaq: AZTA) reported preliminary third-quarter results for fiscal 2022, ending June 30. The revenue is projected at $133 million, a 3% increase year-over-year, with 6% organic growth after currency adjustments. GAAP diluted EPS is estimated between ($0.13) and ($0.08), primarily due to tax impacts, while non-GAAP diluted EPS is expected between $0.08 and $0.12. The Services segment revenue is projected at $85 million, with 6% growth, whereas the Products segment is at $47 million, reflecting a 3% decrease year-over-year.
Azenta, Inc. (Nasdaq: AZTA) has successfully completed its acquisition of Barkey Holding GmbH, a renowned provider of controlled rate thawing devices for medical and biotech sectors. This strategic move enhances Azenta's cold chain capabilities and broadens its customer base in the growing cell and gene therapy market, which currently serves over 100 clients. The acquisition is expected to provide significant synergies by extending Azenta's service offerings across all development and commercialization phases. As of December 1, 2021, Azenta changed its name and ticker from Brooks Automation, Inc. (Nasdaq: BRKS).
Azenta, Inc. (Nasdaq: AZTA) has announced a definitive agreement to acquire Barkey Holding GmbH, a leading provider of controlled rate thawing devices for the medical industry, for approximately €80 million. The acquisition is expected to close in early July 2022 and will enhance Azenta's cold chain product offerings in the growing cell and gene therapy market. Barkey generated around €17 million in revenue over the past year and will add significant capabilities to Azenta's operations. The acquisition is anticipated to be accretive to non-GAAP earnings immediately and to GAAP earnings within a year.
Azenta, Inc. (Nasdaq: AZTA) will participate in the Jefferies Healthcare Conference in New York City on June 9, 2022, with a presentation scheduled for 3:30 PM ET. The event will be available via live webcast on Azenta's investor relations website, with a replay accessible afterward.
As a provider of life sciences solutions, Azenta focuses on cold-chain sample management and genomic services, aiding drug development and clinical research. The company rebranded from Brooks Automation, Inc. on December 1, 2021.
Azenta, Inc. (Nasdaq: AZTA), a leading provider of life sciences solutions, will participate in the UBS Global Healthcare Conference on May 24, 2022, at 2:45 pm ET. The live presentation can be accessed via the investor relations website. Azenta, previously known as Brooks Automation, provides essential cold-chain sample management and genomic services, supporting drug development and advanced therapies across various sectors.
Azenta, Inc. (Nasdaq: AZTA) reported preliminary Q2 results for the period ended March 31, 2022. Revenue from continuing operations reached $146 million, reflecting a 12% year-over-year increase. Life Sciences Services showed significant growth of 19%, primarily in Sample Repository Solutions and Genomics Services. However, the company posted a diluted EPS from continuing operations of ($0.02), down from $0.04 the previous quarter, and operating losses totaled $5 million. Azenta anticipates Q3 revenue between $140 million to $150 million.
Azenta, Inc. (Nasdaq: AZTA) has rescheduled its second fiscal quarter earnings release for 2022 from May 3, 2022, to May 9, 2022, due to delays in the quarter-end closing process following the sale of its Semiconductor Automation business on February 1, 2022. The company anticipates that the second quarter revenue and non-GAAP EPS will remain within the previously issued guidance range. A conference call is scheduled for May 9, 2022, at 4:30 p.m. ET to discuss the financial results.
Azenta, Inc. (Nasdaq: AZTA) will announce its fiscal 2022 second quarter earnings on May 3, 2022, after market close. The results will cover the quarter ending March 31, 2022. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day, accessible via phone and live webcast. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services to major pharmaceutical and biotech companies worldwide.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, featuring a presentation at 9:30 am ET. The event will be accessible via a live webcast on the Azenta investor relations website, with a replay available afterward. Azenta provides comprehensive life sciences solutions, focusing on cold-chain sample management and genomic services for pharmaceutical and biotech industries globally. The company rebranded from Brooks Automation to Azenta, Inc. on December 1 last year.
